Business
Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems
Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance New data expands on findings shared at ATTD and reinforces Eversense 365’s strong patient adherence, glucometrics and hypoglycemic outcomes across an entire year GERMANTOWN, Md., June 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and
About this update from Senseonics Holdings, Inc.
[{"type":"image","alt":"Senseonics Holdings, Inc.","displaySize":"","headline":null,"caption":"Senseonics Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":259,"height":48,"url":"https://media.zenfs.com/en/globenewswire.com/352de1d24c4134f17c1d3a538ac3ac2c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/65Qp4GafRnzuTaIHxi_ZvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4/https://media.zenfs.com/en/globenewswire.com/352de1d24c4134f17c1d3a538ac3ac2c","width":259,"height":48},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/65Qp4GafRnzuTaIHxi_ZvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4/https://media.zenfs.com/en/globenewswire.com/352de1d24c4134f17c1d3a538ac3ac2c","width":259,"height":48}},"lazy":false},{"type":"text","content":"Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance ","length":169,"tagName":"p"},{"type":"text","content":"New data expands on findings shared at ATTD and reinforces Eversense 365’s strong patient adherence, glucometrics and hypoglycemic outcomes across an entire year","length":161,"tagName":"p"},{"type":"text","content":"GERMANTOWN, Md., June 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announces further data from a large real-world evidence study which reveals sustained accuracy, performance and positive impact of Eversense 365 in both open-loop and closed-loop systems. The findings were presented during an oral presentation entitled ‘Real-World Evaluation of the Implantable One-Year Eversense 365 CGM System’ at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, taking place on June 5-8 in New Orleans, U.S. ","length":735,"tagName":"p"},{"type":"text","content":"The data presented at ADA expands on the findings Senseonics previously shared at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) earlier this year, with a dataset including more sensors and users of Eversense 365, the first and only one year CGM- system. The presentation highlighted a real-world analysis of the first 12,360 Eversens...